Evaluation of c-Met, HGF, and HER-2 expressions in gastric carcinoma and their association with other clinicopathological factors

Creative Commons License

Yildiz Y., SÖKMENSÜER C., YALÇIN Ş.

ONCOTARGETS AND THERAPY, vol.9, pp.5809-5817, 2016 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 9
  • Publication Date: 2016
  • Doi Number: 10.2147/ott.s107946
  • Journal Name: ONCOTARGETS AND THERAPY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.5809-5817
  • Hacettepe University Affiliated: Yes

Abstract

Background: Met and HER-2 are proto-oncogenes encoding receptor tyrosine kinase c-Met and HER-2, respectively. Hepatocyte growth factor (HGF) is a ligand of c-Met. The frequency of c-Met, HGF, and HER-2 expressions in gastric cancer and their association with other clinicopathological factors have not been fully understood.